A rationally designed experimental peptide that inhibits the oxidative-stress-sensitive TRPM2 channel. It is included as an international comparison, not a Russian pharmacological development.
An experimental TRPM2-inhibiting peptide studied in cells and mouse ischemic stroke. Included as an international ion-channel comparison to Russian marine-peptide research.
What the studies found
Animal research · 2026
Who or what was studiedTRPM2 electrophysiology and calcium imaging; mouse ischemic-stroke model
Reported finding
M2IP inhibited TRPM2 at submicromolar concentrations in experimental assays and reduced brain injury in a mouse stroke model. It targets an inter-subunit interface involved in channel activation.
Methods, dose & source notes
Study of this preparation · Indexed abstract; full methods not assessed
International comparison, not a confirmed Russian development. Abstract-level findings do not establish human benefit; full dosing, effect sizes and bias appraisal remain needed. Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
These highlights cover selected studies. Open a source for its methods, reported doses and full context.
Compound class
International ion-channel peptide comparator
Research collection
Neuropeptide research · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
No human treatment study in the linked record
Study methods
Channel assays and mouse experiments
Independent replication
Independent replication not established in this collection
Source access
Indexed original abstract; review scope shown per source
Safety evidence
Experimental findings do not establish human safety
Open a topic for the evidence assessment.
More findings, background and history
Ion-channel peptide research
These peptides act on different channels and can have opposite effects. Ms13-1 is a pain-provoking research probe; it should not be grouped with protective findings. M2IP is an international comparator.
International comparator; inhibition and mouse ischemic-injury findings
Channel assays and animal experiments do not establish clinical effectiveness or safety. Each profile links the relevant source and its review scope.
EVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Retrieve the full 2026 mouse-stroke methods: dose, delivery, timing, infarct and functional outcomes, sex, masking and selectivity panel. No human intervention is established by the indexed abstract.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.
Yao J, You Q, Liu X, Zhen W, Fang M, Luo Y, Wu J, Mai Z, Yu P, Yang F, Yang W · Pharmacological research (2026); PMID 41932669
M2IP inhibited TRPM2 at submicromolar concentrations in experimental assays and reduced brain injury in a mouse stroke model. It targets an inter-subunit interface involved in channel activation.
Population / setting
TRPM2 electrophysiology and calcium imaging; mouse ischemic-stroke model
What was checked
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Limitations & review scope
International comparison, not a confirmed Russian development. Abstract-level findings do not establish human benefit; full dosing, effect sizes and bias appraisal remain needed.
Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Source checked 2026-10-17. See the review scope above for the material assessed.